Sanford C. Bernstein Reaffirms Buy Rating for Alnylam Pharmaceuticals, Inc. (ALNY)
Sanford C. Bernstein reissued their buy rating on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a research report sent to investors on Thursday. They currently have a $135.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $94.00.
ALNY has been the subject of a number of other reports. Chardan Capital set a $110.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a buy rating in a research report on Monday, June 12th. ValuEngine raised shares of Alnylam Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, June 13th. Ladenburg Thalmann Financial Services set a $90.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a buy rating in a research report on Monday, July 17th. BidaskClub raised shares of Alnylam Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Saturday, August 5th. Finally, JMP Securities increased their price target on shares of Alnylam Pharmaceuticals from $101.00 to $128.00 and gave the stock an outperform rating in a research report on Wednesday. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of $93.11.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 113.80 on Thursday. The company has a 50-day moving average of $81.14 and a 200-day moving average of $69.12. The stock’s market capitalization is $10.44 billion. Alnylam Pharmaceuticals has a 12-month low of $31.38 and a 12-month high of $118.40.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.12). The company had revenue of $15.93 million during the quarter, compared to analysts’ expectations of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. Alnylam Pharmaceuticals’s revenue for the quarter was up 82.9% compared to the same quarter last year. During the same period last year, the company earned ($1.05) earnings per share. Equities analysts expect that Alnylam Pharmaceuticals will post ($5.19) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Sanford C. Bernstein Reaffirms Buy Rating for Alnylam Pharmaceuticals, Inc. (ALNY)” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.dailypolitical.com/2017/09/24/sanford-c-bernstein-reaffirms-buy-rating-for-alnylam-pharmaceuticals-inc-alny.html.
In other news, President Barry E. Greene sold 76,815 shares of the firm’s stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total value of $7,681,500.00. Following the sale, the president now owns 165,399 shares in the company, valued at $16,539,900. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 4.30% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. QS Investors LLC grew its stake in shares of Alnylam Pharmaceuticals by 59.7% in the second quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 900 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Alnylam Pharmaceuticals by 7.0% in the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 167 shares during the last quarter. CIBC Asset Management Inc acquired a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth $221,000. Neuberger Berman Group LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth $229,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Alnylam Pharmaceuticals in the first quarter worth $148,000. Institutional investors and hedge funds own 94.25% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.